Ziprasidone-is an antipsychotic medication.

Ziprasidone is an antipsychotic medication. It works by changing the effects of chemicals in the brain. Ziprasidone is used to treat schizophrenia and the manic symptoms of bipolar disorder

Ziprasidone-is an antipsychotic medication.

Ziprasidone; Geodon; Zeldox; Ziprasidone hydrochloride

Azona, Zipris, Zipsydon

5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one

• Absorption: Oral
• Distribution: 99%
• Metabolism: Hepatic
• Excretion: via faeces (66%) and urine (20%)

Ziprasidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Ziprasidone is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. 

20 mg twice daily.

For the treatment of schizophrenia and related psychotic disorders.

Blood dyscrasias, neuroleptic malignant syndrome. Somnolence, respiratory tract infections, akathisia, extrapyramidal syndrome, tardive dyskinesia, hyperglycaemia, dizziness, dystonia, headache, GI disturbances, asthenia, agitation, rash, urticaria, visual disturbances, prolonged QT interval, orthostatic hypotension, increased prolactin levels, weight gain, sexual dysfunction, hyperlipidaemia, seizures.

• Increased risk of torsades de pointes with drugs that prolong QT interval e.g. quinidine, dofetilide, sotalol, moxifloxacin, sparfloxacin, pimozide, thioridazine and other Class Ia and III antiarrhythmics.
• Grapefruit juice may increase serum concentration.
• Possible decrease of ziprasidone concentration with St John's Wort.
• Increased CNS depression with kava kava, chamomile.
• Additive hypotensive effect with antihypertensives.
• Antagonistic effect with levodopa and dopamine antagonists.
• Additive sedative effects with other CNS agents, alcohol.

• Concomitant use of oral and IM ziprasidone.
• Recent acute MI, decompensated heart failure, cardiac arrhythmias, conditions that may increase QT interval eg, QT-interval prolongation or history of QT prolongation; prolactin dependent tumours. Lactation.
• Not for treatment of behavioural disorders in elderly with dementia.

Store at 15-30°C (59-86°F).

Molecular weight

412.936

Molecular formula

C21H21ClN4OS

CAS number

146939-27-7

Precautions

• Patients predisposed to significant electrolyte disturbances, esp hypokalaemia, should have a baseline serum potassium and magnesium screening performed and corrected before treatment.
• CNS depression; cerebrovascular disease and significant CV illness; history of seizures; conditions that decrease seizue threshold; predisposition to hypotension; patients at risk of aspiration pneumonia; Parkinson's disease; renal impairment (IM); hepatic impairment; pregnancy.
• Discontinue if persistent QTc measurements >500 msec. May impair ability to drive or operate machinery. Monitor ECG in a patient who shows symptoms of torsades de pointes (e.g. syncope, dizziness, and palpitations).
• Monitor serum electrolytes if on concurrent diuretic therapy. Monitor glucose levels in DM or patient at risk of developing DM.